Gebro Pharma signs a licensing agreement with Recordati for the commercialization of Kentera® in Spain

The Austrian company, Gebro Pharma and the Italian company Recordati, had recently signed an exclusive agreement for distribution, promotion and commercialization of Kentera in Spain.
Kentera® is indicated for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. The urinary incontinence market in Spain has a turnover of 87M Euro.
Kentera® 3.9mg/24 hours is a transdermal patch of oxybutynin and is applied twice weekly. The key advantage of Kentera® over other anticholinergics is its side-effect profile. As a patch, Kentera® avoids pre-systemic gastrointestinal and first-pass metabolism which occur with oral therapies. This metabolism is associated with higher plasma levels of the active metabolite which is associated with anticholinergic side-effects, such as dry mouth and constipation
In Spain, Gebro has built a urology franchise where is currently commercializing Ialuril® for interstitial cystitis and bladder pain syndrome and Vejicur® for the treatment of bladder cancer. With this agreement with Recordati, Gebro Pharma Spain reinforces its urology portfolio.

Sergi Aulinas, CEO at Gebro Pharma Spain expressed “We are very pleased with this agreement because Kentera® offers a new alternative for patients with urinary incontinence that will significantly improve their quality of life. Furthermore, it represents an economic-efficient solution for the sustainability of the public system”.

Overactive bladder in Spain
Overactive bladder (OAB) is a disorder of the bladder-storage function that encompasses frequency, urgency, and urge incontinence, singly or in combination. Symptoms of an overactive bladder occur because the muscles of the bladder are starting to contract involuntarily.

The prevalence of OAB in Spain is around 11,9% of the adult population, 10,8% in males and 12,8% in females. People older than 40 years are more likely to be affected and prevalence increases significantly, being the 24,5% of the adult population; 17,4% in males and 25,6% in females.